Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism

J Am Vet Med Assoc. 2008 May 1;232(9):1321-8. doi: 10.2460/javma.232.9.1321.

Abstract

Objective: To evaluate the effects of twice-daily oral administration of a low-dose of trilostane treatment and assess the duration of effects after once-daily trilostane administration in dogs with naturally occurring hyperadrenocorticism (NOH).

Design: Prospective study.

Animals: 28 dogs with NOH.

Procedures: 22 dogs received 0.5 to 2.5 mg of trilostane/kg (0.23 to 1.14 mg/lb) orally every 12 hours initially. At intervals, dogs were reevaluated; owner assessment of treatment response was recorded. To assess drug effect duration, 16 of the 22 dogs and 6 additional dogs underwent 2 ACTH stimulation tests 3 to 4 hours and 8 to 9 hours after once-daily trilostane administration.

Results: After 1 to 2 weeks, mean trilostane dosage was 1.4 mg/kg (0.64 mg/lb) every 12 hours (n = 22 dogs; good response [resolution of signs], 8; poor response, 14). Four to 8 weeks later, mean dosage was 1.8 mg/kg (0.82 mg/lb) every 12 or 8 hours (n = 21 and 1 dogs, respectively; good response, 15; poor response, 5; 2 dogs were ill). Eight to 16 weeks after the second reevaluation, remaining dogs had good responses (mean dosages, 1.9 mg/kg [0.86 mg/lb], q 12 h [n = 13 dogs] and 1.3 mg/kg [0.59 mg/lb], q 8 h [3]). At 3 to 4 hours and 8 to 9 hours after once-daily dosing, mean post-ACTH stimulation serum cortisol concentrations were 2.60 and 8.09 Pg/dL, respectively.

Conclusions and clinical relevance: In dogs with NOH, administration of trilostane at low doses every 12 hours was effective, although 2 dogs became ill during treatment. Drug effects diminished within 8 to 9 hours. Because of potential adverse effects, lower doses should be evaluated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adrenocortical Hyperfunction / blood
  • Adrenocortical Hyperfunction / drug therapy
  • Adrenocortical Hyperfunction / veterinary*
  • Adrenocorticotropic Hormone / blood*
  • Animals
  • Blood Chemical Analysis
  • Dihydrotestosterone / administration & dosage
  • Dihydrotestosterone / adverse effects
  • Dihydrotestosterone / analogs & derivatives*
  • Dihydrotestosterone / therapeutic use
  • Dog Diseases / blood
  • Dog Diseases / drug therapy*
  • Dogs
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule / veterinary
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Male
  • Prospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Dihydrotestosterone
  • Adrenocorticotropic Hormone
  • trilostane